Why Certara, Inc.’s (CERT) Stock Is Up 5.61%
As of Friday, October 09, Certara, Inc.’s CERT share price has surged by 5.61%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Commentary & Analysis
Why Certara, Inc.’s (CERT) Stock Is Down 6.55%
As of Tuesday, October 06, Certara, Inc.’s CERT share price has dipped by 6.55%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Is Certara, Inc. (CERT) Overvalued?
We dive into why Certara, Inc. (CERT) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Certara, Inc.’s (CERT) Stock Is Down 15.28%
As of Tuesday, August 04, Certara, Inc.’s CERT share price has dipped by 15.28%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About Certara, Inc.'s Q3 Earnings
Certara, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (CERT) missed or beat analyst's expectations.Tudor Pop
Financial Summary
| Share Statistics | CERT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,838.1 | $183.8 | 54% |
|
| Shares Out (Mil) | 152.7 | 45.1 | 71% |
|
| Institutional Ownership | 97.0% | 77.7% | 72% |
|
| Float (Mil) | 112.0 | 40.0 | 63% |
|
| Beta | 1.25 | 1.11 | 73% |
|
| Avg Daily Volume (000s) | 2,668 | 262 | 84% |
|
| Price Change (52-week) |
4.2% | 55.0% | 55% |
|
| Growth | CERT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.5% | 13.5% | 64% |
|
| Net Income (5yr) | 49.6% | 5.4% | 94% |
|
| EPS (5yr) | 51.5% | 15.5% | 93 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (49.5%) | (15.5%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 12 | 11 | |
| Current EPS | $0.094 | $0.340 | $0.391 | |
| Month Ago EPS | $0.093 | $0.341 | $0.389 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.095 | $0.341 | $0.395 | |
| Year/Year Chg | (508.7%) | (3,500%) | (4,490%) | |
| Financials | CERT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $426 | $192 | 39% |
|
| Net Income (TTM) (Mil) | ($64) | ($9) | 14% |
|
| EPS (TTM) | ($0.412) | ($0.900) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | $81 | ($1) | 50% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $295 | $16 | 53% |
|
| Enterprise Value (Q1) (Mil) | $1,942 | $170 | 49% |
|
| Valuation | CERT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.88 | 1.26 | 53% |
|
| P/E | na | 40.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.7 | na |
|
| Ratios | CERT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 62.4% | 61.1% | 75% |
|
| Net Margin | (15.1%) | (22.0%) | 18% |
|
| ROA | (4.4%) | (20.1%) | 30% |
|
| ROE | (6.3%) | (6.3%) | 29% |
|
| Liabilities to Assets | 30.9% | 32.5% | 22% |
|
| F-Score | 6 | 4 | 67% |
|
Passing Stock Screens
As of 11/6/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 14.3% |
| +/- S&P 500: | +6.9 |
